Twenty-four-hour intragastric acidity and plasma gastrin during 3-month treatment with omeprazole in healthy subjects

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 4, 1997, Pages 747-753

  Delchier, J C ^a   Benamouzig, R ^b   Stanescu, L ^a   Ropert, A ^c   Vallot, T ^d   Wirquin, V ^a   Roudot, F ^a   Lamarque, D ^a   Hamelin, B ^e  

^a HENRI MONDOR HOSPITAL   (France)

^b Avicennes   (France)

^c Departements Gastroenterol des Hop   (France)

^d Departements Gastroenterol des Hop   (France)

^e Laboratoires Astra France   (France)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GASTRIN BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LONG TERM EXPOSURE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH PH;

EID: 0030883871     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.00182.x     Document Type: Article

References (11)

1. Clissold SP, Campoli-Richards DM. Omeprazole: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs 1986; 32: 15-47.
2. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut 1983; 24: 270-6.
3. Lanzon-Miller S, Pounder RE, Hamilton MR, et al. Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1987; 1: 239-51.
4. Wilde MI, McTavish D. Omeprazole, an update of its pharmacology and therapeutic use in acid-related disorders. Drugs 1994; 48: 91-132.
5. Lind T, Cederberg C, Idström JP, Lönroth H, Olbe L, Lundell L. 24-hour intragastric acidity and plasma gastrin during long-term treatment with omeprazole or ranitidine in patients with reflux esophagitis. Scand J Gastroenterol 1991; 26: 620-6.
6. Savarino V, Mela GS, Zentilini P, et al. Antisecretory effects of three omeprazole regimens for maintenance treatment in duodenal ulcer. Dig Dis Sci 1994; 39: 1473-82.
7. Vigneri S, Savarino V, Mela GS, et al. A pharmacodynamic study of two omeprazole regimens suitable for long-term treatment of duodenal ulcer. Scand J Gastroenterol 1994; 29: 488-92.
8. Metz DC, Pisegna JR, Fishbeyn VA, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 1992; 103: 1498-508.
9. Walt RP, Gomes M de FA, Wood EC, Logan LH, Pounder RE. Effect of daily oral omeprazole on 24-hour intragastric acidity. Br Med J 1983; 287: 12-4.
10. 2-receptor antagonists. Dig Dis Sci 1990; 35: 976-83.
11. Houben GMP, Hooi J, Hameeteman W, Stockbrügger RW. Twenty-four-hour intragastric acidity: 300 mg ranitidine b.d., 20 mg omeprazole o.m. vs. placebo. Aliment Pharmacol Ther 1995; 9: 649-54.